Trials
1 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Dry Age-related Macular Degeneration
- Main trialPhase 3
- “This study is a Phase 3 multicenter, randomized, controlled, assessor blinded, adaptive study in which subjects will be randomized in a 2:1(OCU410: control) ratio to treatment arm or control arm”In the company’s words, NCT07770828 on ClinicalTrials.gov
Other drugs for Dry Age-related Macular Degeneration
- TinlarebantBelite Bio, Inc · Phase 3
- VonaprumentAnnexon, Inc. · Phase 3
- CemdisiranRegeneron · Phase 3
- PozelimabRegeneron · Phase 3
- BevemipretideMighty Therapeutics Inc. · Phase 2/3
- JNJ-81201887Johnson & Johnson (Janssen) · Phase 2/3
Coming up1
- 30 Jul 2028Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 30 Jul 2028 | Phase 3 Study to Assess Efficacy, Safety & Tolerability of OCU410 For Geographic Atrophy Secondary to Dry AMD |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026